NCATS develops novel approaches to improve the process of joining basic science discoveries with initial testing of therapies in humans.
-
Research
-
- Funding & Notices
- News & Media
- About Translation
-
- About NCATS
-
NCATS Programs & Initiatives
- 3-D Tissue Bioprinting Program
- Assay Development and Screening Technology (ADST)
- Biomedical Data Translator
- Bridging Interventional Development Gaps (BrIDGs)
- Chemistry Technology
- Discovering New Therapeutic Uses for Existing Molecules
- Genetic and Rare Diseases Information Center (GARD)
- Matrix Combination Screening
- Early Translation Branch (ETB)
- A Specialized Platform for Innovative Research Exploration (ASPIRE)
- A Translational Approach to Addressing COVID-19
- Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes
- National COVID Cohort Collaborative (N3C)
- NIH Common Fund Programs
- Rare Diseases Registry Program (RaDaR)
- Tissue Chip for Drug Screening
- Toxicology in the 21st Century (Tox21)
- Functional Genomics Lab
- Therapeutics for Rare and Neglected Diseases (TRND)
- About NCATS
Preclinical Innovation
Organoids Provide Clues to SARS-CoV-2 Brain Infection
A team of researchers used organoids — tiny 3-D tissue models of human brain development — to better understand brain infections caused by SARS-CoV-2.
NCATS researchers, led by Ruili Huang, Ph.D., and Wei Zheng, Ph.D., develop an approach called biological activity-based modeling (BABM), which could speed the search for therapies for COVID-19 and other diseases.
Researchers from NCATS and the National Cancer Institute teamed up to identify and test different drug combinations against small cell lung cancer (SCLC).
Improving the Drug Development ProcessCreating and testing innovative methods to improve and accelerate the drug development process and find new treatments for patients faster.
Repurposing DrugsDiscovering new uses for approved drugs to provide the quickest possible transition from bench to bedside.
Testing & Predictive ModelsDeveloping better model systems for drug and toxicity testing.
Core TechnologiesUsing state-of-the-art resources to enable the ongoing operation of all NCATS translational research activities.
Improving the Drug Development Process
Creating and testing innovative methods to improve and accelerate the drug development process and find new treatments for patients faster.
Discovering new uses for approved drugs to provide the quickest possible transition from bench to bedside.
Developing better model systems for drug and toxicity testing.
Using state-of-the-art resources to enable the ongoing operation of all NCATS translational research activities.
Work with Us
NCATS preclinical programs and resources focus on key obstacles and inefficiencies in the translational process, overcoming bottlenecks that slow the development of new treatments for patients.
Learn more about how to access NCATS programs and expertise.
Inside the NCATS Laboratories
Take a video tour of our labs and see firsthand how our researchers work to get more treatments to more patients more quickly.
Learn more about NCATS’ Achievements in Advancing Translational Sciences.
NCATS Programs & Resources Supporting Preclinical Innovation
- 3-D Tissue Bioprinting Program
- Biomedical Data Translator
- Bridging Interventional Development Gaps (BrIDGs)
- Chemistry Technology
- Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses)
- Extracellular RNA Communication
- Matrix Combination Screening
- NCATS Chemical Genomics Center (NCGC)
- NCATS Pharmaceutical Collection
- Pfizer's Centers for Therapeutic Innovation (CTI) for NIH Researchers
- RNA Interference (RNAi)
- Therapeutics for Rare and Neglected Diseases (TRND)
- Tissue Chip for Drug Screening
- Toxicology in the 21st Century (Tox21)
- Funding & Notices
-